The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

AIM WINNERS & LOSERS: Jadestone Energy up on Montara repairs progress

Wed, 23rd Aug 2023 10:51

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Jadestone Energy PLC, up 25% at 27.60 pence, 12-month range 21p-94.4p. The Asia-Pacific-focused oil and gas firm progresses repairs at its Montara Venture floating production, storage and offloading vessel. Production is temporarily shut in due to a small defect between water tank 4S and oil cargo tank 5C, but repairs have progressed in line with expectations, it says. Will carry out two minor repairs on tank 4P, and has offloaded the oil in tank 5C. Does not expects shut-in to last for more than 60 days. The stock had traded at 35p in late July before Jadestone announced the shut-in.

----------

Bivictrix Therapeutics PLC, up 10% at 14.32p, 12-month range 12p-23p. The biotechnology company focusing on cancer therapies is granted a patent by the US Patent & Trademark Office for its lead asset BVX001. The patent "provides ultimate broad protection" for any antibody drug conjugate therapy targeting leukaemia. Expects a patent to be granted in Japan in the coming weeks, and awaits patent approval in seven countries.

----------

AIM - LOSERS

----------

Bluejay Mining PLC, down 15% at 1.00p, 12-month range 0.9p-7.15p. The Greenland and Finland-focused miner raises GBP600,000 via a private placement of 60.0 million shares to new shareholders at 1.0p each. This represents a 15% discount to Tuesday's closing price of 1.17p. Will use funds for its 100%-owned Hammaslahti copper-zinc-silver-gold project in eastern Finland. Says it is continuing discussions with strategic investors about partnering on one or more of its base metals projects. "The immediate use of these funds will position us for a productive and pivotal second half of 2023, and what we believe could be a transformational 2024," says Executive Chair Robert Edwards.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
17 Apr 2024 14:23

Bivictrix granted FDA orphan drug status for rare cancer treatment

(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said its BVX001 drug has been granted special status by the US Food and Drug Administration....

30 Nov 2023 12:08

IN BRIEF: Bivictrix selects final sequences for lead tumour programme

Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focused on cancer therapies - Says final sequences have been selected f...

15 Nov 2023 13:05

TRADING UPDATES: BiVictriX patent boost; 4Global deal extended

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

15 Nov 2023 12:55

BiVictriX gets patent for its lead asset in Japan

(Sharecast News) - BiVictriX Therapeutics has received a patent grant from the Japanese Patent Office (JPO) for its lead asset BVX001, it announced on...

12 Oct 2023 13:44

BiVictriX posts promising preclinical data on leukaemia candidate

(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.